

Grape King Bio (1707 TT) Investor Presentation (June 2019)





Disclaimer

- The information contained in this confidential document ("Presentation") has been prepared by Grape King Bio (the "Company"). It has not been fully verified and is subject to material updating, revision and further amendment.
- While the information contained herein has been prepared in good faith, neither the Company nor any of its shareholders, directors, officers, agents, employees or advisers gives, has given or has authority to give, any representations or warranties (express or implied) as to, or in relation to, the accuracy, reliability or completeness of the information in this Presentation, or any revision or supplement thereof, or of any other written or oral information made or to be made available to any interested party or its advisers (all such information being referred to as "Information") and liability therefore is expressly disclaimed. Accordingly, neither the Company nor any of its shareholders, directors, officers, agents, employees or advisers takes any responsibility for, or will accept any liability whether direct or indirect, express or implied, contractual, tortious, statutory or otherwise, in respect of, the accuracy or completeness or injury of the Information or for any of the opinions contained herein or for any errors, omissions or misstatements or for any loss, howsoever arising, from the use of this Presentation or the information.
- Neither the issue of this Presentation nor any part of its contents is to be taken as any form of commitment on the part of the Company to proceed with any transaction
 and the right is reserved by the Company to terminate any discussions or negotiations with any prospective investors. In no circumstances will the Company be
 responsible for any costs, losses or expenses incurred in connection with any appraisal or investigation of the Company. In furnishing this Presentation, the Company does
 not undertake or agree to any obligation to provide the recipient with access to any additional information or to update this Presentation or to correct any inaccuracies in,
 or omissions from, this Presentation which may become apparent.
- This Presentation should not be considered as the giving of investment advice by the Company or any of its shareholders, directors, officers, agents, employees or advisers. Each party to whom this Presentation is made available must make its own independent assessment of the Company after making such investigations and taking such advice as may be deemed necessary. In particular, any estimates or projections or opinions contained herein necessarily involve significant elements of subjective judgment, analysis and assumptions and each recipient should satisfy itself in relation to such matters.
- This Presentation includes certain statements that may be deemed "forward-looking statements". All statements in this discussion, other than statements of historical facts, that address future activities and events or developments that the Company expects, are forward-looking statements. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, continued availability of capital and financing, general economic, market or business conditions and other unforeseen events. Prospective Investors are cautioned that any such statements are not guarantees of future performance and that actual results or developments may differ materially from those statements are not guarantees of future performance and that actual results or developments may differ materially from those statements are not guarantees of future performance and that actual results or developments may differ materially from those statements are not guarantees of future performance and that actual results or developments may differ materially from those projected in forward-looking statements.



Investment Highlights



- ✓ We are a leading health food manufacturer in Greater China, specializing in probiotics, mushroom and other herbal-based supplements.
- ✓ We operate the second largest direct-selling company Pro-Partner in Taiwan (2016 market share: 9.8%).



- ✓ We are one of the few health food companies in Taiwan that possess the capability to produce our own raw materials, manufacture products and distribute through own brands and channels.
- ✓ Our expertise in raw materials allow us to develop health supplements serving different benefits.
 Therefore, many of our products are TFDA approved for different health benefits.

Strong R&D capabilities

We are also a frequent winner of major international conventions/competitions in respect to new product design/concept.



- ✓ We have delivered a solid earnings during 2008-2018 (CAGR of 23%/average ROE 21%).
- \checkmark We have maintained more than 60% dividend payout in the past five years.
- ✓ On the back of a growing health and wellness market in Asia, we strive to deliver double digit topline growth through different growth catalysts from our individual business unit.




Company Background

=

2211

Company Milestones



Company Overview : Three core business units



1. Grape King Taiwan

Taiwan own brand & global OEM & ODM

Locus of all key ingredient design, formulation, and production for the whole Group.

2. Pro-Partner

Taiwan direct selling distribution

A differentiated distribution channel with products sold through direct-selling by members under the Pro-Partner brand.




3. Grape King Shanghai


China OEM & ODM

Our manufacturing in China that focuses on OEM and ODM for domestic and global health food companies.


2018 Revenue



2018 Net profit




Complete Product Range





Competitive Strengths- Strong Products Capabilities

We acquired more than 52 patents and published over 20 research papers. Also, we acquired more than 10 TFDA Health Food certifications on our products.





2017-2019 : 8 countries, 61 awards (2019/1-2019/5 : 19 awards)



Competitive Strengths: State-of-the-Art Production Facilities










1. Grape King Taiwan

Taiwan-Grape King Brand Sales Channels





Our best seller – ComeBest Series

32.7% of 2018 revenue

Our second best seller – Antrodia King 9.9% of 2018 revenue

Energy drinks that restore energy and provides necessary vitamins

Our fourth best seller – Ganoderma King

9.2% of 2018 revenue



全面守護消化道 健康順暢每一天

Our third best seller – Probiotics King 9.7% of 2018 revenue

益菌王

ABREAL AND A

Improves digestion and defecation

Strengthens the immune system and suppress allergic reactions 14

建康食品



Pro-Partner Overview

4 key numbers of Pro-Partner

- Largest domestic direct selling company in Taiwan based on revenue.
- One of the fastest growing direct selling companies in Taiwan (20% sales CAGR from 2008 to 2018)

 Second largest overall direct selling company in Taiwan. (2016 market share: 9.8%)

Smallest product range – 28 Health and Beauty products among the top 5



No. 49 in the worldwide direct selling company rankings for 2018 (Source: 2019 DSN Global 100- based on 2018 revenues)

Members# 210,900 157,262 2018 2015 95,802 2012 46,689 2009 7,429 m 6,708 m 3,690 m Sales (NT\$) 1,960 m

Growing sales and members#



Our best seller – Probiotics & Prebiotics 30.6% of 2018 revenue

Our second best seller– Bio Aid 995 15.0% of 2018 revenue

ADMIC MINISTERIO

Bio Aid

Promote healthy digestive system and suppress allergy

康貝兒(N Preblatics & Preblatics

康爾喜



Our future star – Daily Light


Daily Light is our new product launched in 2018 which targets weight management and is popular among our female members.

How is Pro-Partner different from other direct selling companies?






How is Pro-Partner different from other direct selling companies?



Healthy membership growth

The growth rate of our executive distributors are similar to the growth rate of our members in the past years. This implies that our members are proportionally promoted each year based on their contribution to the group.



Pro-Partner member growth rate

20

3. Grape King Shanghai

In the second

Grape King Shanghai Overview

- Established in 1993, Grape King Shanghai was initially targeted as the production base for Grape King's own brand products in China.
- A change in strategy steered by the new management to an OEM/ODM model has reversed several years of losses and turned the operation profitable.
- We see tremendous growth potential for Grape King Shanghai as it continues to acquire more ODM clients locally in China.

Grape King Shanghai operating profit (Rmb m)







General foods supplements


PKL drinks





Health Beauty supplements drinks

Energy drinks





70

Our Goals and Strategies

Our Group Goals

Long-term Goals

- Become a global leading herbal-and probiotics-based supplement supplier.
- Transform Grape King into a group enterprise.
- Grape King own brand, Pro-Partner, and Grape King Shanghai each to contribute 1/3 of consolidated revenue.

ALC IN

Mid-term Goals

- Become a major herbal- and probiotics-based supplement supplier in Asia.
- Establish retail channels in China.
- China business to continue delivering double-digit growth.

Near-term Goals

- Continue to improve brand equity.
- Continue to invest in food safety measures and protection.
- Smooth ramp-up for our capacity expansion.
- Consolidated revenue to resume to double-digit growth.

Our Growth Strategies

03

Key Objectives

Grape King Taiwan

- Brand expansion
- Market share gain
- Accelerate overseas ODM & raw materials supply businesses

Pro-Partner

- Regain growth momentum
- Accurate time to market & improve demand forecast

Grape King Shanghai

- Clients diversification
- Prepping for the probiotics boom

Levers

- ✓ Brand expansion and new channels penetration (offline & online) under company's 50-Year anniversary marketing campaign.
- Continue to research and develop new products that are suitable for the market.
- Continue to participate in overseas exhibitions and competition to promote Grape King's raw material and R&D capabilities.
- Accelerate new product launches from only 1-2 new products to 3-5 products per year.
- Improve supply chain management to ensure no supply disruption.
- KPIs implementation for timely product launches and accuracy in demand forecast.
- Cultivate 10 new customers with the potential of each contributing Rmb 10mn sales per annum
- ✓ Continue to promote Grape King's product expertise in probiotics



Sustainable

double-digit

topline growth

Growing our online sales channel

000



Besides our existing physical retail channels, we are increasing our virtual channel penetration.

Our Virtual channel

- ✓ Grape King online store
- ✓ Online B2C stores
- ✓ TV shopping channels

✓ Social Media

Creative Brand Building

Grape King Antrodia King (liver protection) Stress causes high blood pressure but also harms liver

Creative Brand Building

促進代謝·改變前器生態

30包入

王萨南 益菌王 粉末顆粒 十年熱銷品牌 促進代謝·改慶兩基生態 葡萄干 益菌王 粉末颗粒 **Grape King Probiotics** 十年熱銷品随 調整體質維持消化道機能

Probiotics like a golden warrior who protects your digestion

New Products Pipeline

Weight management



Healthy snacks





Oral protection



Liver protection drinks





Happiness booster

Our Capacity and Expansion Plan

Grape King Specialist Fermentation & Manufacturing Site



| Manufacturing capacity | | | | | | | | | |
|------------------------|------------------|---------------|--|--|--|--|--|--|--|
| Production | Monthly Capacity | | | | | | | | |
| Line | 2018 | 2019 | | | | | | | |
| Capsules | 7 M capsules | 7 M capsules | | | | | | | |
| Fine Granule | 2 M pack | 2 M pack | | | | | | | |
| Liquids-Big CC | 4.2 M bottles | 4.2 M bottles | | | | | | | |
| Liquids-Small CC | 1 M bottles | 1 M bottles | | | | | | | |
| PKL | 1.4 M bottles | 1.4 M bottles | | | | | | | |
| PIC/S | 0.8 M packs | 0.8 M packs | | | | | | | |

Fermentation capacity

| Production | Capacity | | | | |
|--------------|------------|------------|--|--|--|
| Line | 2018 | 2019 | | | |
| Lactobacilli | 25 tons | 25 tons | | | |
| Mushroom | 161.5 tons | 161.5 tons | | | |
| PKL Liquids | 80 tons | 80 tons | | | |

Grape King Shanghai Headquarters



| Manufacturing capacity | | | | | | | | | |
|---------------------------|------------------|---------------|-------|--|--|--|--|--|--|
| Production | Monthl | Cto at | | | | | | | |
| Line | 2018 | 2019 | Start | | | | | | |
| Liquids(Glass) | 15 M bottles | 18 M bottles | 4Q19 | | | | | | |
| Liquids (Retort Pouch) | - | 3 M packs | 3Q19 | | | | | | |
| Powder | 8.2 M pack | 15 M pack | 3Q19 | | | | | | |
| Capsules | - | 7 M capsules | 3Q19 | | | | | | |
| Troches | 23 M capsules | 63 M capsules | 3Q19 | | | | | | |

Grape King Bio-Tech Headquarter



Manufacturing capacity

| Production | Monthly | Chaut | |
|------------|---------|-------|-------|
| Line | 2018 | 2019 | Start |
| | | • | |

8M capsules 13M capsules4Q19 Capsules

Fine Granule 15M pack 15M pack

1.8M packs 1.8M packs -Powder

Grape King Bio-Tech Research Institute



| Fermentation capacity | | | | | | | | |
|-----------------------|------|---------|------|--|--|--|--|--|
| Production | (| Start | | | | | | |
| Line | 2018 | Start | | | | | | |
| Lactobacilli | - | 40 tons | 3Q19 | | | | | |
| Mushroom | - | 60 tons | 3Q19 | | | | | |



Our Sustainability Initiatives

2018



296,450kg Total CO2 emissions reduction

100% Internal product traceability



+52% YoY Employee training hours

94% → 97%

Training participation rate

+265% YoY Volunteer service hours (Including paid time off to volunteer)

+33% YoY

Invested in social & community engagement

100% All employees have free health examinations 0 Major occupational accidents



TWSE corporate governance score (0-100)


2018 92.86 (Rank: 6%~20%)

Financial Performance


Financial Highlights




Historical revenue vs. operating profit



Note: The drop in gross margin is due to higher contribution from Shanghai Grape King with lower gross margin from ODM, but operating margin is around the same.



Historical cash dividend payout



Notes: The payout ratio declined in the past three years due to capacity expansion in Taiwan and Shanghai.

Historical EPS vs. ROCE



15

10

5


0

2008

2009

Revenue Breakdown (2018 v.s. 2017)

Pro-Partner



1.Grape King Taiwan NT\$ 0.4 bn (+10% YoY)

Improved own brand sales in 2H18 owing to new products and our 50-year anniversary sales

2.Pro-Partner NT\$ 7.4 bn (+2% YoY)

Slower membership growth as the business continues to recover


3.Grape King Shanghai NT\$ 1.4 bn (+51% YoY)

Strong OEM/ODM demand from local directselling and Wechat customers

Grape King Shanghai


Grape King Taiwan

2017 Revenue



Revenue Breakdown (1Q19 v.s. 1Q18)

1Q19 Revenue



1.Grape King Taiwan NT\$ 99 m (+22% YoY)

Strong sales through from our own brand products across offline and online channels

2.Pro-Partner NT\$ 1.7 bn (+6% YoY)


Sales momentum further improved on the back of membership growth and new product launches

3.Grape King Shanghai NT\$ 232 m (-13% YoY)

Slower sales due to China's 100-day crack down campaign on irregularities in direct selling, which caused our ODM customers to hold back orders placing/shipment.

Pro-Partner Grape King Shanghai Grape King Taiwan

1Q18 Revenue





Five-Year Income Statement

| (NT\$ m) | 2014 | 4 2015 2016 201 | 2017 2018 1 | YoY (%) | | | | | | | | |
|-----------------------------|---------|-----------------|-------------|---------|---------|---------|-------|--------|------|-------|--------|------|
| | 2014 | 2012 | 2010 | 2017 | 2010 | IQI9 | 2014 | 2015 | 2016 | 2017 | 2018 | 1Q19 |
| Revenue | 6,283 | 7,248 | 9,185 | 9,388 | 9,183 | 2,014 | 11.4 | 15.4 | 26.7 | 2.2 | (2.2) | 4.2 |
| Gross Profit | 5,561 | 6,385 | 7,919 | 7,865 | 7,329 | 1,638 | 11.6 | 14.8 | 24.0 | (0.7) | (6.8) | 6.4 |
| Operating Expenses | (3,961) | (4,573) | (5,685) | (5,610) | (4,979) | (1,167) | 8.4 | 15.4 | 24.3 | (1.3) | (11.2) | 8.0 |
| Operating Profit | 1,600 | 1,812 | 2,234 | 2,254 | 2,350 | 471 | 20.3 | 13.3 | 23.3 | 0.9 | 4.2 | 2.5 |
| Non Operating Income/(Loss) | 89 | 70 | 78 | 151 | 77 | 19 | (8.1) | (21.5) | 11.8 | 92.6 | (49.2) | 28.1 |
| Pretax Income | 1,689 | 1,883 | 2,312 | 2,405 | 2,427 | 490 | 18.4 | 11.4 | 22.8 | 4.0 | 0.9 | 3.3 |
| Tax Expenses | (303) | (336) | (426) | (471) | (537) | (101) | 23.1 | 10.9 | 26.8 | 10.6 | 14.0 | 2.6 |
| Minority interest | (444) | (495) | (590) | (583) | (595) | (126) | 28.4 | 11.5 | 19.2 | (1.3) | 2.1 | 9.4 |
| Net Income to Parent | 942 | 1,052 | 1,297 | 1,352 | 1,295 | 263 | 12.8 | 11.6 | 23.3 | 4.3 | (4.2) | 0.9 |
| Basic EPS (NT\$) | 7.24 | 8.07 | 9.82 | 10.03 | 9.57 | 1.93 | 12.8 | 11.5 | 21.7 | 2.1 | (4.6) | 0.0 |
| Key Financial Ratios (%) | | | | | | | | | | | | |
| Gross Margin | 88.5 | 88.1 | 86.2 | 83.8 | 79.8 | 81.3 | | | | | | |
| Operating Expense Ratio | 63.1 | 63.1 | 61.9 | 59.8 | 54.2 | 57.9 | | | | | | |
| Operating Margin | 25.5 | 25.0 | 24.3 | 24.0 | 25.6 | 23.4 | | | | | | |
| Effect Tax Rate | 17.9 | 17.8 | 18.4 | 19.6 | 22.1 | 20.7 | | | | | | |
| Net Margin | 15.0 | 14.5 | 14.1 | 14.4 | 14.1 | 13.0 | | | | | | |



Five-Year Balance Sheet

| | m) 2014 2015 2016 2017 2018 2 | 2017 2010 | 1010 | YoY (%) | | | | | | | | |
|--------------------------|-------------------------------|-----------|--------|---------|--------|--------|------|-------|--------|--------|--------|-------|
| (NT\$ m) | | 1Q19 | 2014 | 2015 | 2016 | 2017 | 2018 | 1Q19 | | | | |
| Total Assets | 5,369 | 8,612 | 9,550 | 9,892 | 10,648 | 11,030 | 16.0 | 60.4 | 10.9 | 3.6 | 7.6 | 9.9 |
| Cash | 1,374 | 1,433 | 1,899 | 1,920 | 2,050 | 2,000 | 28.6 | 4.3 | 32.6 | 1.1 | 6.8 | 0.3 |
| AR & NR | 98 | 97 | 204 | 160 | 171 | 147 | 14.0 | (1.9) | 111.6 | (21.5) | 6.8 | 38.0 |
| Inventories | 268 | 359 | 435 | 492 | 563 | 552 | 14.1 | 34.0 | 21.0 | 13.1 | 14.4 | 24.5 |
| Fixed Assets | 2,068 | 5,597 | 6,084 | 6,355 | 5,927 | 6,225 | 13.6 | 170.6 | 8.7 | 4.5 | (6.7) | (3.3) |
| Total Liabilities | 1,652 | 4,393 | 3,767 | 3,564 | 3,715 | 3,686 | 17.3 | 165.9 | (14.3) | (5.4) | 4.2 | 12.6 |
| AP & NP | 128 | 153 | 198 | 323 | 262 | 177 | 45.9 | 19.2 | 29.6 | 63.2 | (18.9) | 4.3 |
| Total Borrowing | 0 | 2,439 | 1,206 | 1,022 | 1,119 | 1,304 | - | - | (50.6) | (15.2) | 9.5 | 17.9 |
| Total Equity | 3,717 | 4,220 | 5,783 | 6,328 | 6,933 | 7,343 | 15.4 | 13.5 | 37.1 | 9.4 | 9.6 | 8.6 |
| Key Financial Ratios (%) | | | | | | | | | | | | |
| A/R Turnover Days | 5.3 | 4.8 | 5.9 | 7.0 | 6.5 | 5.7 | | | | | | |
| Inventory Turnover Days | 125.6 | 131.0 | 113.0 | 109.5 | 102.4 | 119.1 | | | | | | |
| A/P Turnover Days | 53.9 | 58.6 | 49.9 | 61.6 | 56.8 | 41.5 | | | | | | |
| Cash Conversion Days | 77.0 | 77.2 | 69.0 | 54.9 | 52.1 | 83.3 | | | | | | |
| ROE (%) | 32.3 | 32.1 | 31.3 | 27.0 | 23.7 | 18.2 | | | | | | |
| ROA (%) | 18.9 | 15.0 | 14.3 | 13.9 | 12.6 | 10.0 | | | | | | |
| Net debt (cash)/Equity % | (37.0) | 23.9 | (12.0) | (14.2) | (13.4) | (9.5) | | | | | | |



Dividend Payout and Capex

| (NT\$ m) | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 |
|---------------|-------|-------|-------|-------|-------|-------|-------|
| Net profit | 619 | 836 | 942 | 1,052 | 1,297 | 1,352 | 1,295 |
| Cash dividend | 482 | 651 | 690 | 730 | 862 | 903 | 883 |
| DPS (NT\$) | 3.7 | 5.0 | 5.3 | 5.59 | 6.4 | 6.68 | 6.5 |
| Payout ratio | 77.9% | 77.9% | 73.2% | 69.4% | 66.5% | 66.8% | 67.9% |
| Cash yield | 3.1% | 3.4% | 2.4% | 2.6% | 3.2% | 2.9% | 3.1% |
| Сарех | 159 | 355 | 187 | 2,635 | 736 | 772 | 1,116 |

Notes:

- 1. Cash yield is calculated based on Grape King's closing share price on June 12, 2019
- 2. The big spike in capex in 2015-2017 is largely due to the investment of 1) Pro-Partner's new headquarter building, 2) the new factory and tourist factory in Pingzhen (Grape King Headquarter), 3) the new factory in Longtan (Grape King Bio-Tech Research Institute), and 4) additional production lines for Grape King Shanghai.
- 3. The estimated capex for 2019 will be used for 1) Grape King Bio-Tech Research Institute, and 2) various upgrade and new production lines projects.




Appendix: Industry Trends

Taiwan health food industry

Taiwan's health food industry is growing

Taiwan health food industry continues to be driven by consumers' increasing interest in healthier lifestyles as a cost-effective way to combat ageing and prevent modern illness.




Source: AC Nielsen

We keep gaining market share in Taiwan

We have been gaining market share in Taiwan's health food industry and we are also the industry leader in both mushroombased supplements and probiotics.

Grape King's market share in Taiwan health food industry




Source: AC Nielsen, Company data

Taiwan direct selling industry

Health food takes up ~60% of direct selling industry in Taiwan

According to Taiwan FTC, health food takes up 60% of the direct selling market share, which shows that direct selling is an important channel for health food products.



Taiwan direct selling industry is strictly regulated with entry barrier



Sales incentive system

- Reasonable product price (mark-up on pricing); 1)
- 2) Reasonable compensation structure (distribution of profit)

Member's system



According to Taiwan's regulation, it is illegal to produce earnings by simply introducing new participants instead of engaging in promotion & selling goods or services. Companies in violation may be subject to imprisonment and/or fines.

Pro-Partner is the only domestic direct selling company in Top 10


| • • • | ers have hig ncentration | , | Pro-Partner has highest sales per product among top 3 players | | | | | | | |
|-------|-----------------------------|-------------|--|-------------------|----------------------|------------------------|--|--|--|--|
| | | | Rank & Market | Members ('000) | Sales contribution | | | | | |
| | Top 10 55% | 0 10 | shares (%) | | Per member (NT\$) | Per product (NT\$m) | | | | |
| | | Pro-Partner | 2 (9.8%) | 200 | 43,300 | 288.7 | | | | |
| | 55/10 | Nu Skin | 3 (5.5%) | 120 | 40,000 | 21.9 | | | | |
| | | Amway | 1 (13.4%) | 350 | 33,857 | 41.0 | | | | |
| | | | | | | /1 | | | | |

Source: Company data, FTC, Taiwan Association of Direct Selling

China health food industry

China's health food industry grew 23% CAGR between 2011-2017


China's health food industry mainly driven by economic growth, disposable income, and rising health awareness. The industry has been growing for the past 6 years.



Source: Forward Business and Intelligence

China direct selling has significant growth from 2011-2016

Direct selling has become an important distribution channel as sales from direct selling has grown from 26% in 2011 to 30% in 2016.




• Despite the latest Administrative Measure of Health Food Registration and Filing having streamlined the certification process for vitamins and minerals, other products still need to go through the "Blue Hat" certification process by the CFDA.



Global probiotics market

Global probiotics market is still growing

According to Statista, global probiotics market has reached US\$40 bn with Asia Pacific region being the largest of all. The market is still increasing and is estimated to grow 7.0% CAGR between 2016-2022.



Grape King is the 7th largest distributor globally

We are ranked as the 7th largest probiotics supplement company globally, this also makes us the largest player in Greater China. Grape King is known for its capability in developing different strains of probiotics that target different health benefits.




Source: Euromonitor

China probiotics market


China probiotics market is expected to reach Rmb 85 bn in 2020

China's probiotic consumption remains at a relatively early stage and the supply is mostly dependent on import. According to ASKCI, China probiotics market is forecasted to reach RMB 85 bn dollars by 2020.




China Probiotics Market (2014-2020)

Source:ASKCI *Notes: China probiotics market includes probiotics supplement, probiotic yoqhurt, and sour milk products.



According to Euromonitor, both Taiwan and China's probiotic supplement market are expected to deliver 27% and 23% of growth in 2016-2021, respectively.









Thank You

For more information, please visit our company website at www.grapeking.com.tw



